Valeo Financial Advisors’s Lipocine LPCN Stock Holding History

Valeo Financial Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-191	Closed	-$5K	–	1242
2021 Q1	$5K	Buy	+191	New	+$5.51K	﹤0.01%	1567

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Valeo Financial Advisors's LPCN Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Lipocine (LPCN) in Q2 2021, closing a stake of 191 shares — an estimated $5K sold.

Valeo Financial Advisors first reported a position in LPCN in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 32 funds tracked by Wall St. Rank hold LPCN as of Q2 2021.

Valeo Financial Advisors reported no remaining Lipocine position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 191 Lipocine shares in Q2 2021, an estimated $5K.
Valeo Financial Advisors first reported a position in Lipocine in Q1 2021 and held it in 1 quarter.
Valeo Financial Advisors's Lipocine position peaked at $5K in Q1 2021.
32 funds tracked by Wall St. Rank held Lipocine as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.